In the majority of patients the distinction between myelodysplastic syndromes (MDSs) and chronic myeloprololiferative disorders is made relatively easily by assessment of clinical, laboratory and morphological characteristics of the peripheral blood and bone marrow. However, the existence of uni-or mulitlineage dysplasia and hyperplastic myelopoiesis in the same patient is well recognized and classified by the World Health Organization (WHO) as myelodysplastic/myeloproliferative disease, unclassifiable. 1 Within this group is a provisional entry referred to as refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (platelets 4600 Â 10 9 /l) (RARS-T). 1 The relationship between dysplasia and the proliferation is not entirely clear, but the recent discovery of a single somatic point mutation in the pseudokinase domain of the Janus kinase 2 (JAK2) resulting in a codon change V617F represents a potential major breakthrough in the pathogenesis of myeloproliferation. Mutation at this site results in the constitutive activation of the JAK2 kinase and thus the activation of the JAK2 pathway. This mutation is present in the majority (495%) of patients with polycythaemia vera and approximately half of those with primary thrombocythaemia and myelofibrosis 2 and others. We have recently reported a high incidence (61%) of the V617F mutation in patients with Budd Chiari syndrome who lack features of a frank proliferative disorder. 3 The prevalence of JAK2 V617F mutation in atypical MPDs or MDS is generally low. 4 Identification of this mutation in MDS identifies a subset of patients with a prominent proliferative component. 5 The lack of a precise molecular definition for most cases of MDS, with the exception of 5qÀ syndrome, testifies to the heterogenous nature of this disorder.
We analysed 70 patients from two European centres with a diagnosis of MDS with ringed sideroblasts of X15% (as defined by the WHO classification), for the presence of the JAK2 V617F mutation. A summary of patient's characteristics is shown in Table 1 . DNA samples for analysis were obtained from archived bone marrow aspirate slides or from fresh peripheral blood taken from patients presenting to our centres. Ethical approval was obtained before the study commenced.
Genomic DNA was prepared using standard methods (Qiagen, House, Crawley, West Sussex, UK). A modified allele-specific PCR (AS-PCR) was used to screen DNA samples. 1 JAK2-mutated DNA samples and control DNAs were further subjected to pyrosequencing (Figure 1 ) to confirm the presence of the mutation. 2, 3 Three out of four JAK2 mutated DNA samples were confirmed mutated by pyrosequencing. However, one sample appeared fully wild-type at the JAK2 allele. This conflicting data can be explained by the fivefold increased sensitivity of the AS-PCR above the pyrosequencing assay. It is likely that the clone size in the pyrosequencing normal patient is much smaller making it indistinguishable from the background in the pyrosequencing assay.
The JAK2 V617F mutation was detected in 4/70 (5.7%) by AS-PCR, which is comparable to previously reported studies. [5] [6] [7] The mean platelet count is higher in the mutated cases at 699 Â 10 9 vs 255 Â 10 9 /l (Po0.0001). The JAK2-positive patients were younger at presentation; 60 vs 70 years (P ¼ 0.031). No statistically significant difference in the mean haemoglobin concentration (9.6 vs 10 g/dl, P ¼ 0.647), white cell count (8.39 Â 10 9 vs 6.8 Â 10 9 /l, P ¼ 0.496) or bone marrow cellularity (90 vs 78%, P ¼ 0.357) was noted between JAK2 V617F-mutated compared to wild-type cases, respectively.
The number of cases within the RARS cohort presenting with thrombocytosis (RARS-T) is 6/70 (8.6%). RARS-T in this cohort is defined as platelet count 4500 Â 10 9 /l. On analysis of patients with RARS-T, the incidence of JAK2 V617F mutation is significantly higher with 4/6 (67%) cases demonstrating the mutation. Of the 66 JAK2 wild-type cases, only 2/66 (3%) presented with platelet count 4500 Â 10 9 /l. The median age of the RARS-T subgroup was 62 (52-71) years with equal male to female patients distribution. Cytogenetic analysis in all cases of RARS-T was normal. Of the JAK2-mutated cases, 3/4 are alive at Table 1 Summary of patient characteristics Letters to the Editor median follow-up of 33 months (range 3-58 months). One patient is transfusion dependent and another transformed to acute myeloid leukaemia within 6 months of diagnosis and died of transplanted-related complication. The higher incidence of JAK2 V617F mutation in cases of RARS-T is consistent with two recently published reports. Szpurka et al. 6 analysed 270 cases of MDS, MDS/MPD and chronic MPD and reported an incidence of 67% (6/9) in RARS-T. A positive pattern of phopho-STAT5 staining was also seen in one case of RARS-T with wild-type JAK2, which may indicate aberrant phopho-STAT5 activation. In a further report by Remacha et al. 7 of 19 cases of RARS, including three cases of RARS-T, the JAK2 V617F mutation was only detected in cases with thromobocytosis. The report by Szpurka et al. 6 also noted no difference in morphological or clinical features on comparison of cases with RARS-T wild-type JAK2 and mutant JAK2, which is consistent with our analysis.
In summary, although the JAK2 V617F mutation is uncommon in MDS RARS/RCMD-RS, this is in contrast to cases of RARS-T where the prevalence is similar to that in essential thrombocythaemia. Whether RARS-T is a distinct clinical entity or part of the spectrum of RARS needs to be established in a larger series. Detection of JAK2 mutation in cases of MDS is of importance as the mutation may identify a cohort of patients which require a different treatment regimen or whose prognosis may be affected by the presence of the mutation. Future treatments may include targeted therapy against the mutated JAK2 clone.
The findings suggest that even in a good prognostic subgroup of MDS, JAK2 mutation provides a proliferative signal to the dysplastic clone, which manifests itself predominantly by increased megakaryocytopoiesis. It is likely the molecular lesions that lead to the occurrence of ring sideroblasts negate the effect of JAK2 activation because of ineffective erythropoiesis and high apoptosis, thus there is no increase in haemoglobin levels. In support of this hypothesis, we have previously demonstrated JAK2 mutation in erythroid burst-forming unit colonies of MDS patients. 5 Further studies are necessary in order to define the role of JAK2 mutation in MDS. Despite evidence suggesting a familial clustering of Hodgkin's lymphoma (HL), [1] [2] [3] [4] [5] [6] there is no clear understanding on the relative contribution of genes and shared environmental factors, including childhood infections, 7, 8 to familial risk. The rarity of familial HL has hampered a detailed analysis of the familial clustering and it has probably contributed to the variation even in recent risk estimates for first-degree relatives, such as 4.9 from Utah 5 and 3.27 from Iceland. 4 The Swedish Family-Cancer Database is the largest populationbased data set with familial information, covering over 10.5 million individuals. We assess here the familial risks of HL in offspring with a parent or a sibling affected with HL, according to age and sex. This will provide a reliable quantification of the familial risk and suggest plausible modes of inheritance. The Swedish Family-Cancer Database includes nearly all individuals born from 1932 onward (second generation) with their biological parents (first generation). This Database was linked to the Swedish Cancer Registry for malignancies diagnosed between 1958 and 2002. Socio-demographic information was obtained by linkage to the nationwide censuses. Standardized incidence ratios (SIRs) were used to estimate familial relative risks computed as the ratio of the number of observed cases to the number of expected cases. Confidence intervals were calculated under the assumption of a Poisson distribution. In order to make a proper comparison between risks in individuals with a parent or a sibling affected, we limited the parental age to 70 years (same as in offspring). The Database contained 3238 (1907 males, 1331 females) offspring with HL.
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The Table 1 shows familial SIRs of HL. The SIR for offspring with a parent affected was 3.05, higher in males compared to females. The highest risks for individuals with an affected parent were found for parental age at diagnosis o40 years (SIR ¼ 6.46). The risk of HL for an affected sibling was 5.56. The highest risks were found for brother-brother (SIR ¼ 8.00) and sister-sister (SIR ¼ 11.75) pairs. Even though the one male twin pair was excluded, the risk remained at 6.40 (see Table 1 footnote).
We confirmed and further quantified the strong familial clustering of HL, [1] [2] [3] [4] [5] [6] being among the highest for any malignancy in the Database; the sibling risk of over 5 ranks second after testicular cancer. 9 The higher risks for siblings compared to parent-offspring pairs suggest a recessive component or childhood shared effects. This is the first study providing familial risks by sex of the proband and the relative. The remarkable high risks found in same-sex siblings is not readily explainable, and it may be due to the small sample size or to yet unrecognized environmental or genetic factors. The familial risks in strata of age suggest higher risks at a relatively young age.
The strength of this study was the availability of populationbased data with registered-based family relations, excluding any type of recall and misclassification bias. Among the limitations, we could not distinguish between heritable genetic and environmental factors as causes of familial aggregation. Nevertheless, the high familial risks observed The Database included an affected male twin pair. When we excluded these two siblings the risk for brother-brother pairs was 6.40 (95% CI, 1.66-15.38).
